NUVB Long Call Strategy
NUVB (Nuvation Bio Inc.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
NUVB (Nuvation Bio Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.66B, a beta of 1.52 versus the broader market, a 52-week range of 1.57-9.75, average daily share volume of 4.4M, a public-listing history dating back to 2020, approximately 273 full-time employees. These structural characteristics shape how NUVB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.52 indicates NUVB has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on NUVB?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current NUVB snapshot
As of May 15, 2026, spot at $4.34, ATM IV 147.80%, IV rank 46.81%, expected move 31.24%. The long call on NUVB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on NUVB specifically: NUVB IV at 147.80% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 31.24% (roughly $1.36 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NUVB expiries trade a higher absolute premium for lower per-day decay. Position sizing on NUVB should anchor to the underlying notional of $4.34 per share and to the trader's directional view on NUVB stock.
NUVB long call setup
The NUVB long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NUVB near $4.34, the first option leg uses a $4.34 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NUVB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NUVB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.34 | N/A |
NUVB long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
NUVB long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on NUVB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on NUVB
Long calls on NUVB express a bullish thesis with defined risk; traders use them ahead of NUVB catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
NUVB thesis for this long call
The market-implied 1-standard-deviation range for NUVB extends from approximately $2.98 on the downside to $5.70 on the upside. A NUVB long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current NUVB IV rank near 46.81% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on NUVB should anchor more to the directional view and the expected-move geometry. As a Healthcare name, NUVB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NUVB-specific events.
NUVB long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NUVB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NUVB alongside the broader basket even when NUVB-specific fundamentals are unchanged. Long-premium structures like a long call on NUVB are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current NUVB chain quotes before placing a trade.
Frequently asked questions
- What is a long call on NUVB?
- A long call on NUVB is the long call strategy applied to NUVB (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With NUVB stock trading near $4.34, the strikes shown on this page are snapped to the nearest listed NUVB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NUVB long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the NUVB long call priced from the end-of-day chain at a 30-day expiry (ATM IV 147.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NUVB long call?
- The breakeven for the NUVB long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NUVB market-implied 1-standard-deviation expected move is approximately 31.24%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on NUVB?
- Long calls on NUVB express a bullish thesis with defined risk; traders use them ahead of NUVB catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current NUVB implied volatility affect this long call?
- NUVB ATM IV is at 147.80% with IV rank near 46.81%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.